Tandem Diabetes Care, Inc.
Here’s whether Tandem Diabetes Care, Inc. (TNDM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-7.95% over 10 days); RSI 29 — oversold; weak 1-year return of -27.5%; 3-month momentum negative (-44.4%); rising volume on a downtrend (distribution, 1.28x avg). Currently 49.5% off its 52-week high. Score: -7/7.
TNDM is trading below its 200-day MA ($18.02) — a key warning sign the longer-term trend is under pressure. An RSI of 29.1 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -27.5% compares to +27.9% for SPY (trailed the market by 55.4%). The current 49.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.